Stephen Lam Chan, MD, FRCP, Chinese University of Hong Kong, Hong Kong, China, discusses the Phase III EMERALD-1 study (NCT03778957), which met its primary endpoint by demonstrating that durvalumab and bevacizumab with transarterial chemoembolization (TACE) significantly improved progression-free survival compared to placebo and TACE in patients with unresectable hepatocellular carcinoma. Whilst there were some concerns about addition of TACE in terms of safety, no additional hemorrhage-related adverse events were reported. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
